Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...

A Cambridge review links long-term particle pollution with increased Parkinson’s risk while highlighting major research gaps.

AbbVie recently received U.S. FDA approval for JUVMO (tavapadon) tablets, the first and only selective D1/D5 receptor agonist ...

Fox was promoted to the companion level of the Order of Canada for his work through the Michael J. Fox Foundation, which has ...

Doctors say clinical trials are needed to understand more after Ed Patrick identified a potential side effect of a ...

Although a clinical setback last year continues to loom in the background, AbbVie’s $8.7 billion bet on Cerevel Therapeutics ...

Researchers at CSIR-Centre for Cellular and Molecular Biology (CCMB) have found possible links between RNA viruses like ...

Parkinson’s disease is a brain disorder that gradually affects movement and many other body functions. It develops as nerve ...

AbbVie stock (ABBV) slipped slightly on Monday, down 0.29%, after the company announced a major regulatory win. The FDA ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

The FDA has approved Juvmo, the first and only dopamine agonist for adults with Parkinson’s disease designed to selectively ...

A new drug for Parkinson’s disease that seem to cause fewer serious side effects than some existing treatments has been ...